Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: The maximal SUV of the stomach is a prognostic factor

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 7, 2012, Pages 1107-1116

  Park, Jun Chul ^a   Lee, Jae Hoon ^a   Cheoi, Kungseok ^a   Chung, Hyunsoo ^a   Yun, Mi Jin ^a   Lee, Hyuk ^a   Shin, Sung Kwan ^a   Lee, Sang Kil ^a   Lee, Yong Chan ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Chemotherapeutic response; Maximal SUV; Pretreatment fluorodeoxyglucose uptake; Prognosis

Indexed keywords

CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84862699614     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2116-x     Document Type: Article

References (40)

1. H Lee H Yang Y Ahn 2002 Gastric cancer in Korea Gastric Cancer 5 177 182 12378346 10.1007/s101200200031
2. SJ Rosenbaum H Stergar G Antoch P Veit A Bockisch H Kühl 2006 Staging and follow-up of gastrointestinal tumors with PET/CT Abdom Imaging 31 25 35 16333707 10.1007/s00261-005-0031-3 1:STN:280:DC%2BD28%2FhsFGjug%3D%3D
3. S Kim KW Kang JS Lee HK Kim HJ Chang JY Choi, et al. 2006 Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer Eur J Nucl Med Mol Imaging 33 148 155 16228236 10.1007/s00259-005-1887-8
4. K Mukai Y Ishida K Okajima H Isozaki T Morimoto S Nishiyama 2006 Usefulness of preoperative FDG-PET for detection of gastric cancer Gastric Cancer 9 192 196 16952037 10.1007/s10120-006-0374-7
5. J Chen J Cheong MJ Yun J Kim JS Lim WJ Hyung, et al. 2005 Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography Cancer 103 2383 2390 15856477 10.1002/cncr.21074
6. T Yoshioka K Yamaguchi K Kubota T Saginoya T Yamazaki T Ido, et al. 2003 Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer J Nucl Med 44 690 699 12732669 1:CAS:528:DC%2BD3sXkt1KisL8%3D
7. CE Reed DH Harpole KE Posther SL Woolson RJ Downey BF Meyers, et al. 2003 Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer J Thorac Cardiovasc Surg 126 1943 1951 14688710 10.1016/j.jtcvs.2003.07.030
8. JB Bomanji DC Costa PJ Ell 2001 Clinical role of positron emission tomography in oncology Lancet Oncol 2 157 164 11902566 10.1016/S1470-2045(00) 00257-6 1:STN:280:DC%2BD387ntFeltg%3D%3D
9. H Vesselle RA Schmidt JM Pugsley M Li SG Kohlmyer E Vallires, et al. 2000 Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography Clin Cancer Res 6 3837 3844 11051227 1:CAS:528:DC%2BD3cXotVyktLo%3D
10. N Ikenaga N Otomo A Toyofuku Y Ueda K Toyoda T Hayashi, et al. 2007 Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors Am Surg 73 1151 1157 18092653
11. AS Allal DO Slosman T Kebdani M Allaoua W Lehmann P Dulguerov 2004 Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose Int J Radiat Oncol Biol Phys 59 1295 1300 15275712 10.1016/j.ijrobp.2003.12.039 1:CAS:528:DC%2BD2cXmtVWhsLk%3D
12. K Ott U Fink K Becker A Stahl H Dittler R Busch, et al. 2003 Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial J Clin Oncol 21 4604 4610 14673049 10.1200/JCO.2003.06.574 1:CAS:528:DC%2BD2cXpsVWqurg%3D
13. K Ott K Herrmann F Lordick H Wieder WA Weber K Becker, et al. 2008 Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study Clin Cancer Res 14 2012 2018 18381939 10.1158/1078-0432.CCR-07-0934 1:CAS:528:DC%2BD1cXkt1akur0%3D
14. HW Chung EJ Lee Y Cho SY Yoon Y So S Kim, et al. 2010 High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma J Cancer Res Clin Oncol 136 1929 1935 20306088 10.1007/s00432-010-0852-5
15. H Hur SH Kim W Kim KY Song CH Park HM Jeon 2010 The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma World J Surg Oncol 8 86 20932345 10.1186/1477-7819-8-86
16. Hamilton SR, Aaltonen LA. World Health Organisation classification of tumours. Pathology and genetics of tumours of the digestive System. Lyon: IARC; 2000.
17. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
18. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
19. PJ Heagerty T Lumley MS Pepe 2000 Time-dependent ROC curves for censored survival data and a diagnostic marker Biometrics 56 337 344 10877287 10.1111/j.0006-341X.2000.00337.x 1:STN:280:DC%2BD3cvotVyntw%3D%3D
20. Y Zheng T Cai Z Feng 2006 Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers Biometrics 62 279 287 16542256 10.1111/j.1541-0420.2005.00441.x
21. R Fluss D Faraggi B Reiser 2005 Estimation of the Youden Index and its associated cutoff point Biom J 47 458 472 16161804 10.1002/bimj.200410135
22. T Higashi E Hatano I Ikai R Nishii Y Nakamoto K Ishizu, et al. 2010 FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma Eur J Nucl Med Mol Imaging 37 468 482 19838700 10.1007/s00259-009-1284-9
23. JS Flier MM Mueckler P Usher HF Lodish 1987 Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes Science 235 1492 1495 3103217 10.1126/science.3103217 1:CAS:528: DyaL2sXhslSis7w%3D
24. YJ Lee A Cho BC Cho M Yun SK Kim J Chang, et al. 2009 High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer Clin Cancer Res 15 2426 2432 19318478 10.1158/1078-0432.CCR-08-2258 1:CAS:528:DC%2BD1MXjvVWksrg%3D
25. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, et al. (18)F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011. doi: 10.1002/cncr.26099.
26. JC Park YC Lee J Kim YJ Kim SK Lee SK Shin, et al. 2010 Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: a single-center, large-volume study in Korea Ann Surg Oncol 17 829 837 19882188 10.1245/s10434-009-0785-x
27. JC Park YC Lee J Kim YJ Kim SK Lee WJ Hyung, et al. 2009 Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients J Surg Oncol 99 395 401 19347884 10.1002/jso.21281
28. A Stahl K Ott WA Weber K Becker T Link J Siewert, et al. 2003 FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings Eur J Nucl Med Mol Imaging 30 288 95 12552348 10.1007/s00259-002-1029-5 1:CAS:528:DC%2BD3sXms1Cmsw%3D%3D
29. T Kawamura T Kusakabe T Sugino K Watanabe T Fukuda A Nashimoto, et al. 2001 Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival Cancer 92 634 641 11505409 10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X 1:CAS:528:DC%2BD3MXmsVyjtLc%3D
30. BS Halpern C Schiepers WA Weber TL Crawford BJ Fueger ME Phelps, et al. 2005 Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion Chest 128 2289 2297 16236886 10.1378/chest.128.4.2289
31. RJ Cerfolio B Ojha AS Bryant V Raghuveer JM Mountz A Bartolucci 2004 The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer Ann Thorac Surg 78 1017 1023 15337041 10.1016/j.athoracsur.2004.02.067
32. S Yuan Y Yu KS Chao Z Fu Y Yin T Liu, et al. 2006 Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer J Nucl Med 47 1255 1259 16883002
33. M Soret SL Bacharach I Buvat 2007 Partial-volume effect in PET tumor imaging J Nucl Med 48 932 945 17504879 10.2967/jnumed.106.035774
34. K Lee S Lee D Kim WJ Kang J Chung S Im, et al. 2006 High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy Clin Cancer Res 12 4232 4236 16857796 10.1158/1078-0432.CCR-05-2710 1:CAS:528:DC%2BD28XntFSmsL4%3D
35. NP Rizk L Tang PS Adusumilli MS Bains TJ Akhurst D Ilson, et al. 2009 Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma J Thorac Oncol 4 875 879 19487968 10.1097/JTO.0b013e3181a8cebf
36. II Na BH Byun HJ Kang GJ Cheon JS Koh CH Kim, et al. 2008 18F-Fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer Clin Cancer Res 14 2036 2041 18381942 10.1158/1078-0432.CCR-07-4074 1:CAS:528:DC%2BD1cXkt1akurg%3D
37. E Mochiki H Kuwano H Katoh T Asao N Oriuchi K Endo 2004 Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer World J Surg 28 247 253 14961197 10.1007/s00268-003-7191-5
38. A Ohtsu 2008 Chemotherapy for metastatic gastric cancer: past, present, and future J Gastroenterol 43 256 264 18458840 10.1007/s00535-008-2177-6 1:CAS:528:DC%2BD1cXlsVOntrc%3D
39. J Park YH Kim 2008 Current approaches to gastric cancer in Korea Gastrointest Cancer Res 2 137 44 19259291
40. YS Kim J Hong SJ Sym SH Park J Park EK Cho, et al. 2010 Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer Cancer Res Treat 42 24 29 20369048 10.4143/crt.2010.42.1.24